BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585-592. [PMID: 20955961 DOI: 10.1016/j.bpg.2010.08.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
2 Hillaire S, Cazals-hatem D, Bruno O, de Miranda S, Grenet D, Poté N, Soubrane O, Erlinger S, Lacaille F, Mellot F, Vilgrain V, Paradis V. Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl 2017;23:1342-7. [DOI: 10.1002/lt.24842] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
3 Martin CR, Zaman MM, Ketwaroo GA, Bhutta AQ, Coronel E, Popov Y, Schuppan D, Freedman SD. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012;303:G474-81. [PMID: 22679000 DOI: 10.1152/ajpgi.00055.2012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
4 Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic fibrosis. Prz Gastroenterol. 2014;9:136-141. [PMID: 25097709 DOI: 10.5114/pg.2014.43574] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
5 Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child 2014;99:443-7. [PMID: 24436365 DOI: 10.1136/archdischild-2013-304159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Stokes CS, Lammert F. Transporters in cholelithiasis. Biological Chemistry 2012;393:3-10. [DOI: 10.1515/bc-2011-226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011;121:523-544. [PMID: 21854363 DOI: 10.1042/cs20110184] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 8.5] [Reference Citation Analysis]
8 Drzymała-Czyż S, Dziedzic K, Szwengiel A, Krzyżanowska-Jankowska P, Nowak JK, Nowicka A, Aringazina R, Drzymała S, Kashirskaya N, Walkowiak J. Serum bile acids in cystic fibrosis patients-glycodeoxycholic acid as a potential marker of liver disease. Dig Liver Dis 2021:S1590-8658(21)00370-4. [PMID: 34305015 DOI: 10.1016/j.dld.2021.06.034] [Reference Citation Analysis]
9 Neri LCL, Simon MISDS, Ambrósio VLS, Barbosa E, Garcia MF, Mauri JF, Guirau RR, Neves MA, Cunha CAP, Nogueira MC, Alves ACDC, Gurmini J, Servidoni MF, Epifanio M, Athanazio R; Grupo de Trabalho das Diretrizes Brasileiras de Nutrição em Fibrose Cística. Brazilian Guidelines for Nutrition in Cystic Fibrosis. Einstein (Sao Paulo) 2022;20:eRW5686. [PMID: 35384985 DOI: 10.31744/einstein_journal/2022RW5686] [Reference Citation Analysis]
10 Clouston AD. Pathologic Features of Hereditary Cholestatic Diseases. Surgical Pathology Clinics 2018;11:313-27. [DOI: 10.1016/j.path.2018.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hirschfield GM. Genetic Determinants of Cholestasis. Clinics in Liver Disease 2013;17:147-59. [DOI: 10.1016/j.cld.2012.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
12 Salas-silva S, Simoni-nieves A, Lopez-ramirez J, Bucio L, Gómez-quiroz LE, Gutiérrez-ruiz MC, Roma MG. Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies. Life Sciences 2019;218:324-39. [DOI: 10.1016/j.lfs.2018.12.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hatano R, Akiyama K, Tamura A, Hosogi S, Marunaka Y, Caplan MJ, Ueno Y, Tsukita S, Asano S. Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice. Hepatology 2015;61:1660-71. [PMID: 25311759 DOI: 10.1002/hep.27565] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
14 Breuer O, Shteyer E, Wilschanski M, Perles Z, Cohen-cymberknoh M, Kerem E, Shoseyov D. Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease. Chest 2016;149:e35-8. [DOI: 10.1016/j.chest.2015.10.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med 2015;36:299-320. [PMID: 25826595 DOI: 10.1055/s-0035-1547347] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
17 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
18 D'Antonio M, Reyna J, Jakubosky D, Donovan MK, Bonder MJ, Matsui H, Stegle O, Nariai N, D'Antonio-Chronowska A, Frazer KA. Systematic genetic analysis of the MHC region reveals mechanistic underpinnings of HLA type associations with disease. Elife 2019;8:e48476. [PMID: 31746734 DOI: 10.7554/eLife.48476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Freischlag KW, Messina J, Ezekian B, Mulvihill MS, Barbas A, Berg C, Sudan D, Reynolds J, Hartwig M, Knechtle S. Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes. Transplant Direct 2018;4:e349. [PMID: 29796420 DOI: 10.1097/TXD.0000000000000785] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
20 Banjar H, Angyalosi G. The road for survival improvement of cystic fibrosis patients in Arab countries. Int J Pediatr Adolesc Med 2015;2:47-58. [PMID: 30805437 DOI: 10.1016/j.ijpam.2015.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 A-Kader HH. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol 2017;11:911-24. [PMID: 28612634 DOI: 10.1080/17474124.2017.1343144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Martonosi ÁR, Soós A, Rumbus Z, Hegyi P, Izsák V, Pázmány P, Imrei M, Váncsa S, Szakács Z, Párniczky A. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Front Med (Lausanne) 2021;8:598382. [PMID: 34386504 DOI: 10.3389/fmed.2021.598382] [Reference Citation Analysis]
23 Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-49. [PMID: 25093717 DOI: 10.3390/ijms150813529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
24 Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, Shunova A, Hector A, Riethmüller J. Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact. Nutrients 2019;11:E656. [PMID: 30889905 DOI: 10.3390/nu11030656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Talbot NC, Caperna TJ, Garrett WM. Growth and Development Symposium: Development, characterization, and use of a porcine epiblast-derived liver stem cell line: ARS-PICM-19. J Anim Sci. 2013;91:66-77. [PMID: 23148238 DOI: 10.2527/jas.2012-5748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Quaglia A, Roberts EA, Torbenson M. Developmental and Inherited Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 111-274. [DOI: 10.1016/b978-0-7020-6697-9.00003-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sellers ZM, Lee LW, Barth RA, Milla C. New Algorithm for the Integration of Ultrasound Into Cystic Fibrosis Liver Disease Screening. Journal of Pediatric Gastroenterology & Nutrition 2019;69:404-10. [DOI: 10.1097/mpg.0000000000002412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
28 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
29 Kelly T, Buxbaum J. Gastrointestinal Manifestations of Cystic Fibrosis. Dig Dis Sci 2015;60:1903-13. [DOI: 10.1007/s10620-015-3546-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
30 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wang Q, Wang B, Saxena V, Miles L, Tiao J, Mortensen JE, Nathan JD. The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. J Surg Res 2018;221:246-56. [PMID: 29229136 DOI: 10.1016/j.jss.2017.08.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
32 Wiecek S, Fabrowicz P, Wos H, Kordys-darmolinska B, Cebula M, Gruszczynska K, Grzybowska-chlebowczyk U, Liu Z. Assessment of Liver Fibrosis with the Use of Elastography in Paediatric Patients with Diagnosed Cystic Fibrosis. Disease Markers 2022;2022:1-8. [DOI: 10.1155/2022/4798136] [Reference Citation Analysis]
33 Cañas T, Maciá A, Muñoz-Codoceo RA, Fontanilla T, González-Rios P, Miralles M, Gómez-Mardones G. Hepatic and Splenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis. Biomed Res Int 2015;2015:517369. [PMID: 26609528 DOI: 10.1155/2015/517369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
34 Wang X, Zhang YF, Yu B, Yang S, Luan J, Liu X, Yang H. Dehydrocostuslactone, a sesquiterpene lactone activates wild-type and ΔF508 mutant CFTR chloride channel. J Asian Nat Prod Res 2013;15:855-66. [PMID: 23799322 DOI: 10.1080/10286020.2013.804814] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Woolfson JP, Schreiber RA, Raveendran S, Chilvers M, Barker C, Guttman OR. Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease. CanLivJ 2021;4:23-32. [DOI: 10.3138/canlivj-2020-0008] [Reference Citation Analysis]
36 Erlinger S. A HCO₃⁻umbrella protects human cholangiocytes against bile salt-induced injury. Clin Res Hepatol Gastroenterol 2012;36:7-9. [PMID: 22206851 DOI: 10.1016/j.clinre.2011.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
38 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
39 Gobato AO, Vasques ACJ, Ribeiro AF, Yamada RM, Hessel G. PREVALENCE OF HEPATIC STEATOSIS AMONG CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS AND ITS ASSOCIATION WITH NUTRITIONAL STATUS. Rev paul pediatr 2019;37:435-41. [DOI: 10.1590/1984-0462/;2019;37;4;00007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Gambella A, Mastracci L, Caporalini C, Francalanci P, Mescoli C, Ferro J, Alaggio R, Grillo F. Not only a small liver - The pathologist's perspective in the pediatric liver transplant setting. Pathologica 2022;114:89-103. [PMID: 35212319 DOI: 10.32074/1591-951X-753] [Reference Citation Analysis]
41 Huynh N, Selvadurai H, Arbuckle S, Cheah E, Dutt S, Thomas G. Severe obstructive biliopathy mimicking biliary atresia in an infant with cystic fibrosis. J Paediatr Child Health 2021. [PMID: 33818837 DOI: 10.1111/jpc.15475] [Reference Citation Analysis]
42 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
44 Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669-681. [PMID: 21045792 DOI: 10.1038/nrgastro.2010.170] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
45 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
46 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
47 Schnúr A, Hegyi P, Rousseau S, Lukacs GL, Veit G. Epithelial Anion Transport as Modulator of Chemokine Signaling. Mediators Inflamm 2016;2016:7596531. [PMID: 27382190 DOI: 10.1155/2016/7596531] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
48 Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012;55:173-183. [PMID: 21932391 DOI: 10.1002/hep.24691] [Cited by in Crossref: 177] [Cited by in F6Publishing: 162] [Article Influence: 17.7] [Reference Citation Analysis]
49 Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
50 Klotter V, Gunchick C, Siemers E, Rath T, Hudel H, Naehrlich L, Roderfeld M, Roeb E. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One 2017;12:e0178784. [PMID: 28575039 DOI: 10.1371/journal.pone.0178784] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]